ARP Americas LP Acquires Shares of 1,900 West Pharmaceutical Services Inc. (NYSE:WST)

ARP Americas LP acquired a new stake in West Pharmaceutical Services Inc. (NYSE:WST) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 1,900 shares of the medical instruments supplier’s stock, valued at approximately $432,000.

A number of other large investors have also added to or reduced their stakes in the business. BlackRock Inc. increased its stake in shares of West Pharmaceutical Services by 3.7% during the first quarter. BlackRock Inc. now owns 8,461,300 shares of the medical instruments supplier’s stock worth $1,288,234,000 after purchasing an additional 302,380 shares during the period. State Street Corp increased its stake in shares of West Pharmaceutical Services by 2.0% during the first quarter. State Street Corp now owns 2,787,626 shares of the medical instruments supplier’s stock worth $424,416,000 after purchasing an additional 53,552 shares during the period. WCM Investment Management LLC increased its stake in shares of West Pharmaceutical Services by 5.4% during the first quarter. WCM Investment Management LLC now owns 1,410,819 shares of the medical instruments supplier’s stock worth $214,797,000 after purchasing an additional 72,700 shares during the period. Geode Capital Management LLC increased its stake in shares of West Pharmaceutical Services by 7.3% during the first quarter. Geode Capital Management LLC now owns 937,568 shares of the medical instruments supplier’s stock worth $142,636,000 after purchasing an additional 64,051 shares during the period. Finally, Invesco Ltd. increased its stake in shares of West Pharmaceutical Services by 4.5% during the first quarter. Invesco Ltd. now owns 873,359 shares of the medical instruments supplier’s stock worth $132,968,000 after purchasing an additional 37,651 shares during the period. Hedge funds and other institutional investors own 90.59% of the company’s stock.

A number of brokerages have recently weighed in on WST. Zacks Investment Research reiterated a “buy” rating and set a $219.00 target price on shares of West Pharmaceutical Services in a research note on Sunday, May 3rd. BofA Securities upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and set a $280.00 target price on the stock in a research note on Tuesday, July 21st. Finally, Bank of America raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and set a $280.00 price target on the stock in a research report on Tuesday, July 21st.

In other West Pharmaceutical Services news, SVP David A. Montecalvo sold 14,508 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $264.82, for a total value of $3,842,008.56. Following the sale, the senior vice president now owns 15,732 shares of the company’s stock, valued at approximately $4,166,148.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

NYSE:WST traded down $0.09 during trading hours on Friday, reaching $268.87. 603,081 shares of the company were exchanged, compared to its average volume of 490,724. The company has a market capitalization of $19.85 billion, a P/E ratio of 70.94, a P/E/G ratio of 3.63 and a beta of 1.13. West Pharmaceutical Services Inc. has a 1-year low of $124.53 and a 1-year high of $273.78. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.96 and a quick ratio of 2.11. The business has a 50 day moving average of $229.94 and a 200 day moving average of $185.69.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $1.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.34. The business had revenue of $527.20 million for the quarter, compared to the consensus estimate of $496.09 million. West Pharmaceutical Services had a return on equity of 19.01% and a net margin of 14.69%. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.89 earnings per share. As a group, equities research analysts anticipate that West Pharmaceutical Services Inc. will post 4.27 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date of this dividend is Tuesday, July 28th. West Pharmaceutical Services’s dividend payout ratio is currently 19.75%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Story: What is a capital gain?

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.